Related Experiment Video
Updated: Aug 8, 2026
10:18
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its
S A Pileri1, S Dirnhofer, Ph Went
1Chair of Pathologic Anatomy & Lymphoma Unit, L. & A. Seràgnoli Institute of Haematology and Clinical Oncology, Bologna University, Via Massarenti 9, 40138 Bologna, Italy. pileri@almadns.unibo.it
Histopathology
|December 4, 2002
Summary
Diffuse large B-cell lymphoma (DLBCL) is a common aggressive lymphoid cancer. Research highlights its heterogeneity and suggests subclassification based on pathogenic pathways for better prognosis and targeted therapies.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoid malignancy globally.
- DLBCL encompasses aggressive lymphomas with large neoplastic cells, B-cell origin, and requiring intensive chemotherapy.
- DLBCL presents heterogeneously in nodal and extranodal sites, affecting both immunocompetent and immunosuppressed individuals.
Purpose of the Study:
- To review recent advancements in DLBCL pathobiology.
- To discuss the heterogeneity of DLBCL and its implications for classification and treatment.
- To contribute to the ongoing scientific discourse on DLBCL.
Main Methods:
- Review of immunophenotypic, tissue microarray, and molecular studies.
- Analysis of clinical findings and cell morphology.
- Consideration of pathobiological pathways.
Main Results:
- DLBCL exhibits significant variability in morphology and clinical presentation.
- Primary mediastinal DLBCL is recognized as a distinct clinicopathological entity.
- Heterogeneity suggests subclassification based on pathogenic pathways is crucial for prognosis and therapy.
Conclusions:
- Morphological classification alone is insufficient for DLBCL.
- Subclassification based on distinct pathogenic pathways offers greater prognostic and therapeutic relevance.
- Further research into DLBCL pathobiology is essential for personalized medicine.
